Hospital Universitario de la Princesa -ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study

    Farmacia Hospitalaria

2022

  1. Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer

    Frontiers in Oncology, Vol. 12

  2. Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 12, pp. 2020-2029

2018

  1. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

    Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098

2015

  1. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice

    International Journal of Clinical Pharmacy, Vol. 37, Núm. 5, pp. 808-814

2013

  1. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: Dosing patterns and effectiveness in daily clinical practice

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 559-565

  2. Equipotent doses of erythropoiesis-stimulating agents in outpatients with anaemia secondary to chronic kidney disease

    Latin American Journal of Pharmacy, Vol. 32, Núm. 3, pp. 454-458

  3. Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: A cost-minimization analysis

    International Journal of Clinical Pharmacy, Vol. 35, Núm. 3, pp. 463-468

2012

  1. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis

    Journal of Pharmacy and Pharmaceutical Sciences, Vol. 15, Núm. 3, pp. 355-360